The South Texas Blood & Tissue Center is participating in a U.S. Food and Drug Administration (FDA) investigational program for blood centers to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.
While COVID-19 currently has no proven treatment, it is possible that convalescent plasma, which contains antibodies to the virus that causes COVID-19, may provide passive immunity to certain patients with severe forms of the illness.
Potential donors must be completely free of symptoms for 14 days prior to donation.
Recovered patients who meet these criteria along with all FDA requirements for blood and plasma donation can contact us about participating by clicking below.
Our team will contact you within 24 to 48 hours. If you have any questions, please call 210-731-2719 between 8 a.m. – 5 p.m., Monday through Friday. All appointments MUST be made by phone and donations are made at our Donor Pavilion, Shavano, Northeast, Southeast and Westover Hills locations.
The South Texas Blood & Tissue Center is not a COVID-19 “testing center” and is not doing widespread antibody testing. We are a blood center and are specifically collecting plasma from recovered COVID-19 patients, per FDA requirements, to be used as a treatment for patients who are currently sick with the virus.
At this time, asymptomatic donors who have received a COVID-19 vaccine can donate convalescent plasma 14 days from a positive test. Symptomatic donors may donate convalescent plasma 14 days from the date of recovery.
The guidance is subject to change following further review by the FDA.
Anyone who has received authorized or licensed monoclonal antibody therapy (specifically Regeneron) for treatment of COVID-19, or investigational COVID-19 monoclonal antibody therapy as a participant in a clinical trial, is deferred 3 months from donating convalescent plasma.
Potential donors must also be completely free of symptoms for 14 days prior to donation and meet all FDA requirements for blood and plasma donation.
Please contact us at 210-731-2719 between 8 a.m. – 5 p.m., Monday through Friday if you have any other questions about eligibility.
If I meet the criteria to be a donor, what can I expect?
I have a scheduled convalescent plasma donation appointment, what should I expect?
How many patients can my donation help?
A single dose of convalescent plasma is 200mL. On the average, one donor can provide 3 – 4 doses, which can help treat 3 – 4 people.
COVID-19 convalescent plasma has not been approved or licensed by FDA; COVID-19 convalescent plasma has been authorized by FDA under an EUA; COVID-19 convalescent plasma is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
For more than 45 years, the nonprofit South Texas Blood & Tissue Center has focused on a critical purpose: to save and improve lives.
Inspired by a group of physicians, our organization was formed to provide blood to the South Texas region – ensuring a safe and adequate blood supply through proper testing, storage and distribution to hospitals. This essential service allows front-line workers to focus on the direct care of patients, with confidence that this lifesaving resource will be there when it’s needed most.
But we didn’t stop there. Over the years, we’ve evolved as the needs of our patients and hospitals have changed, driven to save lives in as many ways as possible.
We couldn’t do this without donors like you. We understand that the gift of donation is a personal, powerful choice that has the potential to touch a life. Today, we offer many ways to make a difference that include:
Our team has also expanded its programs, partnering with leaders within the healthcare industry to develop a wide range of therapies. We’ve recently developed programs to collect and distribute COVID-19 convalescent plasma, as well as improve trauma care.